Argomenti e Notizie
sull'Osteoporosi
con raccolte
bibliografiche su
PubMed Logo
a cura del
Dott. C.Tarozzi
Bologna
Anno 23°
Num. 138
Recens. 2729
Aderiamo allo standard HONcode per l'affidabilità dell'informazione medica questo sito aderisce fin dal 2004 allo standard HONcode per l'affidabilità dell'informazione medica. Verifica qui.
Rassegna - Alimenti e Calcio - Questionari - T-Score - Valore di un Test - Calcolatori - Contatti - Digitalia - Radioactivity
Ricerca nell'archivio di questo sito...
 ?  
Nuova bibliografia selezionata fino al mese di agosto 2018 (recensioni 28) Ordina per Autore - Titolo - Rivista
Akkawi I, Zmerly H.
Osteoporosis: Current Concepts.
Joints. 2018 Jun 14;6(2):122-127.

Aljohani S, Gaudin R, Weiser J, Tröltzsch M, Ehrenfeld M, Kaeppler G, Smeets R, Otto S.
Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series.
J Craniomaxillofac Surg. 2018 May 31. pii: S1010-5182(18)30333-0.

Behera J, Tyagi N.
Exosomes: mediators of bone diseases, protection, and therapeutics potential.
Oncoscience. 2018 Jun 23;5(5-6):181-195.

Benucci M, Saviola G, Baiardi P, Abdi-Ali L, Povino MR, Dolenti S, Campostrini L, Sacco S, Manfredi M, Rossini M.
Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids.
Clin Exp Rheumatol. 2009 Jul-Aug;27(4):567-73.

Bhattoa HP.
Laboratory aspects and clinical utility of bone turnover markers.
EJIFCC. 2018 Jul 11;29(2):117-128. eCollection 2018 Jul.

Bone HG, Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Fitzpatrick LA, Mitlak B, Papapoulos S, Rizzoli R, Dore RK, Bilezikian JP, Saag KG.
ACTIVExtend: 24 Months of Alendronate after 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
J Clin Endocrinol Metab. 2018 May 24.

Carda S, Invernizzi M, Sainaghi PP, Cisari C.
Acute pseudogout following intravenous neridronate for osteoporosis.
J Rheumatol. 2010 May;37(5):1076.

Cho H, Byun JH, Song I, Kim HY, Ha YC, Kim TY, Lee YK, Jang S.
Effect of improved medication adherence on health care costs in osteoporosis patients.
Medicine (Baltimore). 2018 Jul;97(30):e11470.

Cohn M, Gianakos AL, Grueter K, Rosen N, Cong GT, Lane JM.
An Update on the Comprehensive Approach to Fragility Fractures.
J Orthop Trauma. 2018 Jul 20.

Forni GL, Perrotta S, Giusti A, Quarta G, Pitrolo L, Cappellini MD, D'Ascola DG, Borgna Pignatti C, Rigano P, Filosa A, Iolascon G, Nobili B, Baldini M, Rosa A, Pinto V, Palummeri E.
Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study.
Br J Haematol. 2012 Jul;158(2):274-282.

Gatti D, Rossini M, Viapiana O, Idolazzi L, Adami S.
Clinical development of neridronate: potential for new applications.
Ther Clin Risk Manag. 2013;9:139-47.

Gaudio A, Fiore CE.
Successful neridronate therapy in pregnancy-associated osteoporosis.
Clin Cases Miner Bone Metab. 2016 Sep-Dec;13(3):241-243.

Habib ZA.
Bisphosphonates in the treatment of osteoporosis: a review of skeletal safety concerns.
Expert Rev Endocrinol Metab. 2017 Jan;12(1):59-71.

Inoue Y, Mitsunaga K, Yamamoto T, Chiba K, Yamaide F, Nakano T, Morita Y, Yamaide A, Suzuki S, Arima T, Yamaguchi KI, Tomiita M, Shimojo N, Kohno Y.
Early use of alendronate as a protective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: a cross-sectional study.
Pediatr Rheumatol Online J. 2018 Jun 18;16(1):36.

Leali PT, Balsano M, Maestretti G, Brusoni M, Amorese V, Ciurlia E, Andreozzi M, Caggiari G, Doria C.
Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study.
Clin Cases Miner Bone Metab. 2017 May-Aug;14(2):153-156.

Majumdar SR, McAlister FA, Johnson JA, Rowe BH, Bellerose D, Hassan I, Lier DA, Li S, Maksymowych WP, Menon M, Russell AS, Wirzba B, Beaupre LA.
Comparing Strategies Targeting Osteoporosis to Prevent Fractures after an Upper Extremity Fracture (C-STOP Trial): A Randomized Controlled Trial.
J Bone Miner Res. 2018 Jul 24.

McClung MR.
Drug holidays in women treated for postmenopausal osteoporosis.
Menopause. 2018 Jul 23.

Muratore M, Quarta E, Quarta L.
Intramuscular neridronate in patients with rheumatoid arthritis using corticosteroids: evaluation of treatment adherence in a randomized, open-label comparison with other bisphosphonates.
Acta Biomed. 2013 Jun 1;84(1):23-9.

Perobelli RF, Xavier B, Silveira ARD, Remuzzi GL, Motta LGJ, Dalmora SL.
Quantitation of the monoclonal antibody Denosumab by bioassay and validated LC methods.
Int J Biol Macromol. 2018 Jul 23;119:96-104.

Rossini M, Viapiana O, Kalpakcioglu B, Dhangana R, Gatti D, Braga V, Fracassi E, Adami S.
Long-term effects of neridronate and its discontinuation in patients with primary hyperparathyroidism.
Calcif Tissue Int. 2011 Jul;89(1):21-8.

Starr J, Tay YKD, Shane E.
Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures.
Curr Osteoporos Rep. 2018 Aug;16(4):519-529.

Sølling ASK, Harsløf T, Langdahl B.
The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis.
Ther Adv Musculoskelet Dis. 2018 Jun;10(5-6):105-115.

Uehara M, Nakamura Y, Takahashi J, Kamimura M, Isobe F, Yamaguchi T, Kosho T, Uchiyama S, Suzuki T, Kato H.
Efficacy of denosumab therapy for neurofibromatosis type 1 with osteoporosis and history of fractures: a case report.
Ther Clin Risk Manag. 2018 Jul 16;14:1243-1246. doi:

Viswanathan M, Reddy S, Berkman N, Cullen K, Middleton JC, Nicholson WK, Kahwati LC.
Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
JAMA. 2018 Jun 26;319(24):2532-2551.

Winzenrieth R, Humbert L, Di Gregorio S, Bonel E, García M, Del Rio L.
Effects of osteoporosis drug treatments on cortical and trabecular bone in the femur using DXA-based 3D modeling.
Osteoporos Int. 2018 Jul 4.

Winzenrieth R, Humbert L, Di Gregorio S, Bonel E, García M, Del Rio L.
Effects of osteoporosis drug treatments on cortical and trabecular bone in the femur using DXA-based 3D modeling.
Osteoporos Int. 2018 Jul 4.

Wolffenbuttel BHR, Abma EM, Appelman-Dijkstra NM.
[The denosumab dilemma: to be stopped after 5 years or to be continued in patients with osteoporosis?].
Ned Tijdschr Geneeskd. 2018 May 14;162. pii: D2831. Dutch.

Wolverton D, Elliott DP.
Evaluating the Evidence Behind Treating Osteoporosis in the Oldest Adults.
Consult Pharm. 2018 Jun 1;33(6):308-316.

(Vers. 2.1)  Modificato il 2-8-2018
http://www.tarozzi.net   
questo sito aderisce ai principi HONCODE    disclaimer